Trial record 19 of 31 for:    " August 06, 2008":" September 05, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.

This study has been terminated.
(Strategic decision)
Sponsor:
Information provided by:
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00741741
First received: August 22, 2008
Last updated: October 22, 2010
Last verified: October 2010
  Purpose

The purpose of this study is: to determine the safety, (local) tolerability and plasma exposure over time of single intramuscular (IM) doses of 600 and 1200 mg of a new formulation (F006) of TMC278LA, to determine the safety, (local) tolerability and long-term plasma exposure over time of 2 dose regimens of 4 monthly IM doses of a new formulation (F006) of TMC278LA., To determine the safety, (local) tolerability and long-term plasma exposure over time of 1 dose regimen of 4 monthly subcutaneous (SC) doses of a new formulation (F006) of TMC278LA.


Condition Intervention Phase
HIV-1
Drug: TMC278
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Phase I, Double Blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Multiple (Monthly) Intramuscular and Subcutaneous Doses of TMC278LA.

Resource links provided by NLM:


Further study details as provided by Tibotec Pharmaceuticals, Ireland:

Primary Outcome Measures:
  • Safety, (local) tolerability and TMC278 PK of multiple doses of a novel formulation of TMC278LA throughout the study till WK24, WK28, WK32 or beyond WK32 (i.e. till TMC278 is below 20 ng/ml and till all AEs are resolved/stabilized)

Enrollment: 20
Study Start Date: July 2008
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients aged between 18 and 55 years, extremes included
  • Non-smokers for at least 3 months prior to selection
  • Normal weight as defined by a Body Mass Index (BMI: weight in kg divided by height in meters squared) of 18.0 to 30.0 kg/m2, extremes included
  • Informed Consent Form signed voluntarily
  • Able to comply with protocol requirements
  • Normal 12-lead electrocardiogram (ECG) (in triplicate) at screening including: a) normal sinus rhythm (heart rate [HR] between 40 and 100 bpm), b) QTc interval <= 450 ms, c) QRS interval lower than 120 ms, d) PR interval <= 220 ms
  • Healthy on the basis of a pre-study physical examination, medical history, vital signs and the results of blood biochemistry and hematology tests and a urinalysis carried out at screening
  • Patient agrees not to participate in any other clinical trial until 6 weeks after being informed that his/her TMC278 exposure is below 20 ng/ml (all panels)
  • Females participating in the clinical study must be of non-childbearing potential (e.g. surgically sterilized or postmenopausal with no menstrual bleeding for at least 2 years prior the clinical study
  • If the patient is a sexually active man and not surgically sterilized, he must be willing to abstain from sexual intercourse, or use a condom plus another form of contraception (e.g., spermicide, IUD, birth control pills taken by female partner, diaphragm with spermicide) if engaging in sexual intercourse with a woman who could become pregnant. This will avoid pregnancy caused by possibly damaged sperm. Males must use a condom during sexual intercourse with pregnant or lactating females. Male patients must not father a child from administration of the first dose and up to one month after the last dose of the IMP.

Exclusion Criteria:

  • Past history of heart arrhythmias (extrasystolic, tachycardia at rest) or having baseline prolongation of QTc interval > 450 ms, history of risk factors for Torsade de Pointes syndrome (hypokalemia, family history of long QT Syndrome)
  • History or suspicion of alcohol, barbiturate, amphetamine, recreational or narcotic drug use that could impact compliance to protocol requirements and/or safety
  • Hepatitis A infection (confirmed by hepatitis A antibody), or hepatitis B infection (confirmed by hepatitis B surface antigen), or hepatitis C infection (confirmed by hepatitis C virus antibody) or HIV-1 or HIV-2 infection at screening
  • A positive urine drug test at study screening. Urine will be tested for the presence of amphetamines, benzodiazepines, cocaine, cannabinoids, opioids, methadone and barbiturates
  • Currently active or underlying gastro-intestinal, cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory or infectious disease
  • History of clinically relevant skin disease such as, but not limited to, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria
  • History of drug allergy such as, but not limited to, sulfonamides and penicillins, or drug allergy witnessed in previous clinical studies with experimental drugs
  • Use of concomitant medication, including over-the-counter products, herbal medication (including St. John's Wort) and dietary supplements, except for paracetamol (acetaminophen) or ibuprofen in a period of 14 days before the first IMP administration
  • Participation in an investigational drug trial within 30 days prior to the first injection with IMP, Donation of blood or plasma in the 60 days preceding the injection with the IMP, Having previously participated in a clinical study with oral TMC278 (previously known as R278474) or TMC278LA, Vulnerable subjects (e.g., persons kept in detention)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00741741

Sponsors and Collaborators
Tibotec Pharmaceuticals, Ireland
Investigators
Study Director: Tibotec Pharmaceuticals Clinical Trial Tibotec Pharmaceutical Limited
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00741741     History of Changes
Other Study ID Numbers: CR015295
Study First Received: August 22, 2008
Last Updated: October 22, 2010
Health Authority: Ireland: Irish Agriculture and Food Development Authority

Keywords provided by Tibotec Pharmaceuticals, Ireland:
TMC278-C150
TMC278-TiDP15-C150
HIV-1 infected patients
Intramuscular or subcutaneous injection
Nanosuspension
Therapy
Prevention
Healthy volunteers
HIV Infections

ClinicalTrials.gov processed this record on August 21, 2014